Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/32901
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSTESSEL, Bjorn-
dc.contributor.authorVancuchelen, Charlotte-
dc.contributor.authorBRUCKERS, Liesbeth-
dc.contributor.authorGeebelen, Laurien-
dc.contributor.authorCALLEBAUT, Ina-
dc.contributor.authorVANDENBRANDE, Jeroen-
dc.contributor.authorPallens, Ben-
dc.contributor.authorVan Tornout, Michiel-
dc.contributor.authorOry, Jean-Paul-
dc.contributor.authorvan Halem, Karlijn-
dc.contributor.authorMESSIAEN, Peter-
dc.contributor.authorHERBOTS, Lieven-
dc.contributor.authorRamaekers, Dirk-
dc.contributor.authorDubois, Jasperina-
dc.date.accessioned2020-12-14T09:53:50Z-
dc.date.available2020-12-14T09:53:50Z-
dc.date.issued2020-
dc.date.submitted2020-11-24T12:51:43Z-
dc.identifier.citationThrombosis Research, 194 , p. 209 -215-
dc.identifier.issn0049-3848-
dc.identifier.urihttp://hdl.handle.net/1942/32901-
dc.description.abstractIntroduction: An individualised thromboprophylaxis was implemented in critically ill patients suffering from coronavirus disease 2019 (COVID-19) pneumonia to reduce mortality and improve clinical outcome. The aim of this study was to evaluate the effect of this intervention on clinical outcome. Methods: In this mono-centric, controlled, before-after study, all consecutive adult patients with confirmed COVID-19 pneumonia admitted to ICU from March 13th to April 20th 2020 were included. A thromboprophylaxis protocol, including augmented LMWH dosing, individually tailored with anti-Xa measurements and twice-weekly ultrasonography screening for DVT, was implemented on March 31th 2020. Primary endpoint is one-month mortality. Secondary outcomes include two-week and three-week mortality, the incidence of VTE, acute kidney injury and continuous renal replacement therapy (CRRT). Multiple regression modelling was used to correct for differences between the two groups. Results: 46 patients were included in the before group, 26 patients in the after group. One month mortality decreased from 39.13% to 3.85% (p < 0.001). After correction for confounding variables, one-month mortality was significantly higher in the before group (p = 0.02, OR 8.86 (1.46, 53.75)). The cumulative incidence of VTE and CRRT was respectively 41% and 30.4% in the before group and dropped to 15% (p = 0.03) and 3.8% (p = 0.01), respectively. After correction for confounding variables, risk of VTE (p = 0.03, 6.01 (1.13, 32.12)) and CRRT (p = 0.02, OR 19.21 (1.44, 255.86)) remained significantly higher in the before group. Conclusion: Mortality, cumulative risk of VTE and need for CRRT may be significantly reduced in COVID-19 patients by implementation of a more aggressive thromboprophylaxis protocol. Future research should focus on confirmation of these results in a randomized design and on uncovering the mechanisms underlying these observations. .-
dc.description.sponsorshipThis study is part of the Limburg Clinical Research Program (LCRP) UHasselt-ZOL-Jessa, supported by the foundation Limburg Sterk Merk, province of Limburg, Flemish government, Hasselt University, Ziekenhuis Oost-Limburg and Jessa Hospital.-
dc.language.isoen-
dc.publisherPERGAMON-ELSEVIER SCIENCE LTD-
dc.rights2020 Elsevier Ltd. All rights reserved-
dc.subject.otherCOVID-19-
dc.subject.otherThromboprophylaxis-
dc.subject.otherVenous thromboembolism-
dc.subject.otherMortality-
dc.subject.otherContinuous renal replacement therapy-
dc.titleImpact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study-
dc.typeJournal Contribution-
dc.identifier.epage215-
dc.identifier.spage209-
dc.identifier.volume194-
local.format.pages7-
local.bibliographicCitation.jcatA1-
dc.description.notesStessel, B (corresponding author), Jessa Hosp Hasselt, Dept Intens Care & Anesthesiol, Virga Jesse Campus,Stadsomvaart 11, B-3500 Hasselt, Belgium.-
dc.description.notesbjorn.stessel@jessazh.be-
dc.description.otherStessel, B (corresponding author), Jessa Hosp Hasselt, Dept Intens Care & Anesthesiol, Virga Jesse Campus,Stadsomvaart 11, B-3500 Hasselt, Belgium. bjorn.stessel@jessazh.be-
local.publisher.placeTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1016/j.thromres.2020.07.038-
dc.identifier.pmid32788120-
dc.identifier.isiWOS:000568490100037-
dc.contributor.orcidCallebaut, Ina/0000-0002-6666-6783-
dc.identifier.eissn1879-2472-
local.provider.typewosris-
local.uhasselt.uhpubyes-
local.description.affiliation[Stessel, Bjorn; Vancuchelen, Charlotte; Geebelen, Laurien; Callebaut, Ina; Vandenbrande, Jeroen; Pallens, Ben; Van Tornout, Michiel; Ory, Jean-Paul; Dubois, Jasperina] Jessa Hosp, Dept Intens Care & Anesthesiol, Hasselt, Belgium.-
local.description.affiliation[Stessel, Bjorn; Callebaut, Ina; Messiaen, Peter] UHasselt, Fac Med & Life Sci, LCRC, B-3590 Diepenbeek, Belgium.-
local.description.affiliation[Geebelen, Laurien] Hasselt Univ, Data Sci Inst, I BioStat, Martelarenlaan 42, B-3500 Hasselt, Belgium.-
local.description.affiliation[van Halem, Karlijn; Messiaen, Peter] Jessa Hosp, Dept Infect Dis & Immun, Hasselt, Belgium.-
local.description.affiliation[Herbots, Lieven] Jessa Hosp, Dept Cardiol, Hasselt, Belgium.-
local.description.affiliation[Herbots, Lieven] Jessa Hosp, Coronary Care Unit, Hasselt, Belgium.-
local.description.affiliation[Ramaekers, Dirk] Jessa Hosp, Hasselt, Belgium.-
local.description.affiliation[Ramaekers, Dirk] Univ Leuven, Leuven Inst Healthcare Policy LIHP, Leuven, Belgium.-
local.uhasselt.internationalno-
item.fullcitationSTESSEL, Bjorn; Vancuchelen, Charlotte; BRUCKERS, Liesbeth; Geebelen, Laurien; CALLEBAUT, Ina; VANDENBRANDE, Jeroen; Pallens, Ben; Van Tornout, Michiel; Ory, Jean-Paul; van Halem, Karlijn; MESSIAEN, Peter; HERBOTS, Lieven; Ramaekers, Dirk & Dubois, Jasperina (2020) Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study. In: Thrombosis Research, 194 , p. 209 -215.-
item.validationecoom 2021-
item.fulltextWith Fulltext-
item.contributorSTESSEL, Bjorn-
item.contributorVancuchelen, Charlotte-
item.contributorBRUCKERS, Liesbeth-
item.contributorGeebelen, Laurien-
item.contributorCALLEBAUT, Ina-
item.contributorVANDENBRANDE, Jeroen-
item.contributorPallens, Ben-
item.contributorVan Tornout, Michiel-
item.contributorOry, Jean-Paul-
item.contributorvan Halem, Karlijn-
item.contributorMESSIAEN, Peter-
item.contributorHERBOTS, Lieven-
item.contributorRamaekers, Dirk-
item.contributorDubois, Jasperina-
item.accessRightsOpen Access-
crisitem.journal.issn0049-3848-
crisitem.journal.eissn1879-2472-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
1-s2.0-S0049384820303297-main.pdfPublished version558.17 kBAdobe PDFView/Open
Show simple item record

SCOPUSTM   
Citations

36
checked on Dec 4, 2025

WEB OF SCIENCETM
Citations

36
checked on Dec 1, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.